Klin Padiatr 2012; 224(03): 207-210
DOI: 10.1055/s-0032-1306277
Report
© Georg Thieme Verlag KG Stuttgart · New York

Newly Diagnosed Immune Thrombozytopenia – German Guideline Concerning Initial Diagnosis and Therapy

Leitlinie zur Diagnose und Therapie der neu diagnostizierten Immunthrombozytopenie
W. Eberl
1   Pediatric Hematology and Oncology, Klinikum Braunschweig, Germany
,
R. Dickerhoff
2   Pediatric Hematology and Oncology, University Duesseldorf, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
13 April 2012 (online)

Abstract

Newly diagnosed immune thrombocytopenia occurs in 3–5/100 000 children < 14 y per year. Bleeding symptoms do not correlate with platelet count. Diagnostic approach includes history, clinical examination and analysis of blood count with blood smear by experienced hematologist. Additional investigations are only necessary in atypical cases and cases with additional symptoms or inadequate response to therapy. The decision to treat ITP should be made cautiously and not entirely be based on the platelet count. Decisions based on clinical symptoms and progress of the illness are more reasonable. There is no evidence, that therapy at the time of diagnosis influences the further course and can avoid intracerebral hemorrhage.

Zusammenfassung

Die neu diagnostizierte ITP betrifft 3–5/100 000 Kinder pro Jahr. Die klinische Symptomatik korreliert nicht mit der Plättchenzahl. Die Diagnose ist vom erfahrenen Pädiater oder Hämatologen durch Anamnese, klinische Untersuchung sowie Erstellung eines Blutbildes mit mikroskopischer Differenzierung des Ausstrichs zu stellen. Zusätzliche Untersuchungen sind nur bei atypischen Verläufen, zusätzlichen Symptomen oder unzureichendem Therapieansprechen erforderlich. Die Indikation zur Behandlung einer ITP ist zurückhaltend zu stellen und gründet sich nicht allein auf die Thrombozytenzahl. Ein Vorgehen auf der Grundlage der Klinik setzt sich immer mehr durch. Es gibt keine Evidenz, dass eine Therapie bei Diagnosestellung den weiteren Verlauf beeinflussen und eine zerebrale Blutung verhindern kann. Es gibt keine Evidenz, dass eine Therapie einem nicht blutenden Patienten einen Vorteil bringt.

 
  • Literature

  • 1 Althaus K, Najm J, Greinacher A. MYH9 Related Platelet Disorders – Often Unknown and Misdiagnosed. Klin Padiatr 2011; 223: 120-125
  • 2 Benesch M. How far should we go with cost-utility analysis when treating children with Acute Idiopathic Thrombocytopenic Purpura?. Pediatr Blood Cancer 2008; 50: 433
  • 3 Bierling P, Godeau B. Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on. Vox sang 2004; 86: 8-14
  • 4 Bolton-Maggs PHB. Idiopathic thrombocytopenic purpura. Arch Dis Child 2000; 83: 220-222
  • 5 Bolton-Maggs PHB, Dickerhoff R, Vora AJ. The nontreatment of childhood ITP (or “The art of medicine consists of amusing the patient until nature cures the disease”). Semin Thromb Hemost 2001; 27: 269-275
  • 6 Bolton-Maggs P. Acute immune thrombocytopenic purpura. Hamostaseologie 2009; 29: 74-75
  • 7 British Committee for Standards in Haematology General Haematolgy Task Force . Guidelines for the investigation and management of idiopathic thrombocytopenic purpura. in adults, children and in pregnancy. Br J Haematol 2003; 120: 574-596
  • 8 Bruin M, Bierings M, Uiterwaal C et al. Platelet count, previous infection and FCGR2B genotype predict development of chronic disease in newly diagnosed idiopathic thrombocytopenia in childhood: results of a prospective study. Br J Haematol 2004; 127: 561-567
  • 9 Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 2002; 141: 683-688
  • 10 Buchanan GR, Adix L. Current challenges in the management of children with idiopathic thrombocytopenic purpura. Pediatr Blood Cancer 2006; 47: 681-684
  • 11 Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenic purpura: A retrospective analysis. J Pediatr Hematol Oncol 2003; 25: 660-664
  • 12 Calpin C, Dick P, Poon A et al. Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out leukaemia?. Arch Pediatr Adolesc Med 1998; 152: 345-347
  • 13 Choudhary DR, Naithani R, Mahapatra M et al. Intracranial hemorrhage in childhood immune thrombocytopenic purpura. Pediatr Blood Cancer 2009; 52: 529-531
  • 14 Dickerhoff R, von Rücker A. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr 2000; 137: 629-632
  • 15 Dominguez V, Govezensky T, Gevorkian G et al. Low platelet counts alone do not cause bleeding in experimental model of immune thrombocytopenic purpura in mice. Haematologica 2003; 88: 679-687
  • 16 Farmand S, Baumann U, von Bernuth H et al. Interdisciplinary AWMF Guideline for the Diagnostics of Primary Immunodeficiency. Klin Padiatr 2011; 223: 378-385
  • 17 George JN. Initial management of immune thrombocytopenic purpura in children: is supportive counseling without therapeutic intervention sufficient?. J Pediatr 2000; 137: 598-600
  • 18 George JN, Vesely SK. Immune thrombocytopenic purpura – Let the treatment fit the patient. N Engl J Med 2003; 349: 903-905
  • 19 Goerge T, Ho-Tin-Noe B, Carbo C et al. Inflammation induces hemorrhage in thrombocytopenia. Blood 2008; 111: 4958-4964
  • 20 Imbach P, Kühne T, Müller D et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 2006; 46: 351-356
  • 21 Imbach P. When a child with immune thrombocytopenia experiences life-threatening bleeding. Klin Padiatr 2010; 222: 337-339
  • 22 Iyori H, Bessho F, Ookawa H et al. Intracranial hemorrhage in children with immune thrombocytopenic purpura. Ann Hematol 2000; 79: 691-695
  • 23 Kattamis AC, Shankar S, Cohen AR. Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G. J Pediatr 1997; 130: 281-283
  • 24 Kees-Folts D, Abt AB, Domen RE et al. Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura. Pediatr Nephrol 2002; 17: 91-96
  • 25 Kühne T, Freedman J, Semple JW et al. Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura. J Pediatr 1997; 130: 17-24
  • 26 Kühne T. Idiopathic thrombocytopenic purpura in childhood: controversies and solutions. Pediatr Blood Cancer 2006; 47: 650-652
  • 27 Kühne T, Imbach P. Idiopathische thrombozytopenische Purpura im Kindesalter. Monatsschr Kinderheilkd 2006; 154: 533-539
  • 28 Lilleyman JS. Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Arch Dis Child 1994; 71: 251-253
  • 29 Lilleyman JS. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol 1999; 105: 871-875
  • 30 Neunert CE, Buchanan GR, Imbach P et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008; 112: 4003-4008
  • 31 Pansy J, Minkov M, Dengg R et al. Evaluating bleeding severity in children with newly diagnosed immune thrombocytopenia: a pilot study. Klin Padiatr 2010; 222: 374-377
  • 32 Provan D, Stasi R, Newland AC et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186
  • 33 Psaila B, Petrovic A, Page L et al. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP). Blood 2009; 114: 4777-4783
  • 34 Rajantie J, Zeller B, Treutiger I et al. Vaccination associated thrombocytopenic purpura in children. Vaccine 2007; 25: 1838-1840
  • 35 Reed Gaines A. Disseminated intravascular coagulation associated with acute hemoblobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005; 106: 1532-1537
  • 36 Rodeghiero F, Stasi R, Gernsheimer T et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-2393
  • 37 Roganovic J, Letica-Crepulja M. Idiopathic thrombocytopenic purpura: a 15-year natural history study at the Children’s Hospital Rijeka, Croatia. Pediatr Blood Cancer 2006; 47: 662-664
  • 38 Rosthoj S, Hedlund-Treutiger I, Rajantie J et al. Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children: a prospective nordic study of an unselected cohort. J Pediatr 2003; 143: 302-307
  • 39 Salama A, Kiesewetter H, Kalus U et al. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thromb Haemost 2008; 100: 762-765
  • 40 Salama A, Rieke M, Kiesewetter H et al. Experiences with recombinant FVII in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature. Ann hematol 2009; 88: 11-15
  • 41 Streif W, Knöfler R, Eberl W. Inherited Disorders of Platelet Function in Pediatric Clinical Practice: A Diagnostic Challenge. Klin Padiatr 2010; 222: 203-208
  • 42 Sutor AH. Acute immune thrombocytopenia in childhood. Are we treating the platelet count?. Semin Thromb Hemost 1998; 24: 545-548
  • 43 Tarantino MD. The treatment of immune thrombocytopenic purpura in children. Curr Hematol Rep 2006; 5: 89-94
  • 44 Trebo MM, Frey E, Gadner H et al. Subcutaneous anti_D globulin application is a safe treatment option of immune thrombocytopenia in children Ann Hematol 2010; 89 (415) 418
  • 45 Treutiger I, Rajantie J, Zeller B et al. Does treatment of newly diagnosed idiopathic thrombocytopenic purpura reduce morbidity?. Arch Dis Child 2007; 92: 704-707
  • 46 Uetz B, Wawer A, Nathrath M et al. Intracranial hemorrhage in immune thrombocytopenia (ITP): fatal course in spite of maximum therapy. Klin Padiatr 2010; 222: 383-385
  • 47 Yildiz N, Ardic F, Deniz S. Very early onset steroid-induced avascular necrosis of the hip and knee in a patient with idiopathic thrombocytopenic purpura. Inter Med 2008; 47: 1989-1992